US Cosmetic Procedure Using Fat from Deceased Donors Sparks Medical and Ethical Controversy
US Cosmetic Procedure Using Fat from Deceased Donors Sparks Medical and Ethical Controversy
———————————–
A cosmetic procedure involving injections of processed fat tissue obtained from deceased donors has sparked controversy in the United States over patient safety, regulatory oversight and the ethics of commercializing human tissue.
Known as AlloClae, the technique was developed by US company Tiger Aesthetics and marketed in 2024 as an alternative to traditional fat transfer, allowing body augmentation without liposuction. The company says more than 2,000 people received the injections between May 2025 and July 2026.
The procedure has faced regulatory challenges, particularly in New York, where authorities refused to authorize its distribution over concerns about its regulatory classification. Medical concerns have also emerged following reports of complications in a patient, although a direct causal link has not been established.
Beyond safety questions, medical ethicists have raised concerns about whether deceased donors fully understand that their donated tissue could be used for commercial cosmetic procedures. The controversy has intensified calls for greater transparency, informed consent and stricter oversight of the commercial use of human tissue.
